Stay updated on Taldefgrobep Alfa in SMA Clinical Trial
Sign up to get notified when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.

Latest updates to the Taldefgrobep Alfa in SMA Clinical Trial page
- Check5 days agoChange DetectedThe page’s revision was updated to v3.5.3, replacing v3.5.2, indicating a minor update to the Study Details page.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedRevision history updated: added v3.5.2 and removed v3.5.0.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedRevision: v3.4.3 updated to v3.5.0.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. No other content or functionality appears to be affected.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded detailed extension phase dosing for taldefgrobep alfa and placebo, including open-label extension (OLE) phase. Updated the protocol to version 3.4.2 with related update dates (2026-01-30, 2026-02-04, 2026-06).SummaryDifference0.5%

- Check91 days agoChange DetectedNotice about government funding and operation status was added, and the page version updated from v3.4.0 to v3.4.1; these changes do not alter study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Taldefgrobep Alfa in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.